中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 4
Apr.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(4): 823-828

Construction and analysis of a predictive model for posthepatectomy recurrence in patients with hepatocellular carcinoma based on preoperative CXCL13 measurement

DOI: 10.3969/j.issn.1001-5256.2021.04.020
  • Received Date: 2020-09-24
  • Accepted Date: 2020-12-16
  • Published Date: 2021-04-20
    Abstract
  •   Objective  To investigate the serological markers associated with posthepatectomy recurrence in patients with hepatocellular carcinoma, and to establish a prognostic model to evaluate whether palliative hepatectomy is suitable for such patients.  Methods  A total of 111 patients with hepatocellular carcinoma who underwent hepatectomy in the Affiliated Cancer Hospital of Zhengzhou University from February 2009 to July 2013 and received follow-up were enrolled. Basic clinical data were collected and the patients were divided into recurrence group and non-recurrence group according to whether recurrence was observed during follow-up. The t-test was used for comparison of normally distributed continuous data between two groups and the Wilcoxon rank sum test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test was used for comparison of categorical data between two groups. Survival curves were plotted using the Kaplan-Meier method, and survival differences were analyzed using the log-rank test. A Cox regression analysis was used to perform univariate and multivariate analyses, and the area under the ROC curve (AUC) was used to evaluate prediction efficiency.  Results  The Kaplan-Meier survival curves showed that the patients with low alpha-fetoprotein (AFP), alkaline phosphatase, gamma-glutamyl transpeptidase (GGT), and fibrinogen and high CXCL13 had a longer median time to recurrence (P < 0.05). AFP (hazard ratio [HR][95%CI]=1.69(1.03~2.79), P=0.039), GGT (HR[95%CI]=1.89(1.14~3.14), P=0.014), and CXCL13 (HR[95%CI]=0.54(0.33~0.89), P=0.015) were independent factors associated with posthepatectomy recurrence. The prognostic index PI=0.526×AFP+0.637×GGT-0.616×CXCL13 established based on these factors had an AUC of 0.87, a sensitivity of 93.75%, and a specificity of 63.64% in predicting recurrence within 0-3 months after palliative hepatectomy, with a significant reduction in prediction efficiency for recurrence within 0-6 months (AUC=0.68) or a longer period of time. The recurrence prediction efficiency of this model for palliative hepatectomy was significantly higher than that for radical resection.  Conclusion  The prognostic model established based on CXCL13, AFP, and GGT can be used to evaluate the risk of early recurrence after palliative hepatectomy and thus helps clinicians to make diagnosis and treatment decisions based on patients' benefits.

     

    • FullText(HTML)
  • loading
    • References(18)
  • [1]
    BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
    [2]
    ZHOU Z, LIN X, LIN N, et al. Establishment and predictive value of clinical prediction model for the recurrence after resection of hepatocellular carcinoma[J/CD]. Chin J Hepat Surg(Electronic Edition), 2017, 6(3): 192-196. DOI: 10.3877/cma.j.issn.2095-3232.2017.03.010.

    周正, 林晓, 林楠, 等. 肝细胞癌切除术后复发的临床预测模型的建立及其预测价值[J/CD]. 中华肝脏外科手术学电子杂志, 2017, 6(3): 192-196. DOI: 10.3877/cma.j.issn.2095-3232.2017.03.010.
    [3]
    ZLOTNIK A, YOSHIE O. The chemokine superfamily revisited[J]. Immunity, 2012, 36(5): 705-716. DOI: 10.1016/j.immuni.2012.05.008.
    [4]
    LI B, SU H, CAO J, et al. CXCL13 rather than IL-31 is a potential indicator in patients with hepatocellular carcinoma[J]. Cytokine, 2017, 89: 91-97. DOI: 10.1016/j.cyto.2016.08.016.
    [5]
    DUAN Z, GAO J, ZHANG L, et al. Phenotype and function of CXCR5+CD45RA-CD4+ T cells were altered in HBV-related hepatocellular carcinoma and elevated serum CXCL13 predicted better prognosis[J]. Oncotarget, 2015, 6(42): 44239-44253. DOI: 10.18632/oncotarget.6235.
    [6]
    BINDEA G, MLECNIK B, TOSOLINI M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer[J]. Immunity, 2013, 39(4): 782-795. DOI: 10.1016/j.immuni.2013.10.003.
    [7]
    Ministry of Health of the People's Republic of China. Diagnosis, management, and treatment of hepatocellular carcinoma (V2011)[J]. J Clin Hepatol, 2011, 27(11): 1141-1159. DOI: 10.3969/j.issn.1001-5256.2011.11.004

    中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版)[J]. 临床肝胆病杂志, 2011, 27(11): 1141-1159. DOI: 10.3969/j.issn.1001-5256.2011.11.004
    [8]
    LI CY. Expression and effect of CXCL 13 chemokine in hepatocellullar carcinoma[D]. Changchun: Jilin University, 2017.

    李春艳. 趋化因子CXCL13在肝细胞癌中的表达及作用机制研究[D]. 长春: 吉林大学, 2017.
    [9]
    LI C, KANG D, SUN X, et al. The effect of C-X-C motif chemokine 13 on hepatocellular carcinoma associates with Wnt signaling[J]. Biomed Res Int, 2015, 2015: 345413. DOI: 10.1155/2015/345413.
    [10]
    FÖRSTER R, MATTIS AE, KREMMER E, et al. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen[J]. Cell, 1996, 87(6): 1037-1047. DOI: 10.1016/s0092-8674(00)81798-5.
    [11]
    KIM CH, ROTT LS, CLARK-LEWIS I, et al. Subspecialization of CXCR5+ T cells: B helper activity is focused in a germinal center-localized subset of CXCR5+ T cells[J]. J Exp Med, 2001, 193(12): 1373-1381. DOI: 10.1084/jem.193.12.1373.
    [12]
    CUCCHETTI A, PISCAGLIA F, CATURELLI E, et al. Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population[J]. Ann Surg Oncol, 2009, 16(2): 413-422. DOI: 10.1245/s10434-008-0232-4.
    [13]
    CHEN K, YANG HJ, DENG XF, et al. Risk factors of primary hepatocellular carcinoma patients early term recurrence after radical resection and prediction model establishment[J]. Chin J Cancer Prev Treat, 2018, 25(5): 344-348. https://www.cnki.com.cn/Article/CJFDTOTAL-QLZL201805009.htm

    陈凯, 杨洪吉, 邓小凡, 等. 肝癌根治性切除术后早期复发危险因素分析及预测模型构建[J]. 中华肿瘤防治杂志, 2018, 25(5): 344-348. https://www.cnki.com.cn/Article/CJFDTOTAL-QLZL201805009.htm
    [14]
    PAN YX, CHEN JC, FANG AP, et al. A nomogram predicting the recurrence of hepatocellular carcinoma in patients after laparoscopic hepatectomy[J]. Cancer Commun (Lond), 2019, 39(1): 55. DOI: 10.1186/s40880-019-0404-6.
    [15]
    YE YJ, LIU B, CHEN W, et al. Prognosis and staging system analysis of hepatocellular carcinoma patients with negative serum alpha-fetoprotein[J]. J Clin Hepatol, 2019, 35(3): 535-541. DOI: 10.3969/j.issn.1001-5256.2019.03.017.

    叶颖剑, 刘波, 陈伟, 等. 血清AFP阴性的肝细胞癌患者预后及分期系统分析[J]. 临床肝胆病杂志, 2019, 35(3): 535-541. DOI: 10.3969/j.issn.1001-5256.2019.03.017.
    [16]
    LIU AX, WANG HQ, BO WT, et al. Clinical efficacy and prognostic factors analysis of hepatectomy for hepatocellular carcinoma[J]. Chin J Dig Surg, 2019, 18(4): 368-374. DOI: 10.3760/cma.j.issn.1673-9752.2019.04.012.

    刘爱祥, 王海清, 薄文滔, 等. 肝细胞癌肝切除术的临床疗效及预后因素分析[J]. 中华消化外科杂志, 2019, 18(4): 368-374. DOI: 10.3760/cma.j.issn.1673-9752.2019.04.012.
    [17]
    XUE Y, ZHANG J, BAI Y, et al. Establishment and validation of a prognostic model for hepatocellular carcinoma after radical liver resection[J]. J BUON, 2019, 24(4): 1420-1428. http://www.researchgate.net/publication/336824473_Establishment_and_validation_of_a_prognostic_model_for_hepatocellular_carcinoma_after_radical_liver_resection/download
    [18]
    Department of Medical Administration. National Health and Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001 -5256.2020.02.007.

    中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001 -5256.2020.02.007.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (601) PDF downloads(45) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return